18F-FDG PET与18F-FES PET对1-2级雌激素受体阳性乳腺癌分期的诊断准确性
这项前瞻性多中心先导研究纳入41例1或2级雌激素受体阳性乳腺癌患者,比较18F-FES PET与18F-FDG PET的分期准确性,结果显示18F-FDG PET正确分期29/41例(71%),18F-FES PET正确分期34/41例(83%),差异无统计学意义(P = .18),两种方法检测转移性疾病的敏感度均为100%(95% CI:59,100),特异度均为91%(95% CI:76,98)。
要点
- 18F-FDG PET正确分期29/41例(71%),18F-FES PET正确分期34/41例(83%),差异无统计学意义(P = .18)。
- 区域淋巴结分期中,18F-FDG PET错误分期6/44例(14%),18F-FES PET全部正确(P = .02)。
- 两种方法检测转移性疾病的敏感度均为100%(95% CI:59,100),特异度均为91%(95% CI:76,98)。
核心结论
- 在这项前瞻性先导研究中,没有证据表明18F-FES PET与18F-FDG PET在1或2级雌激素受体阳性乳腺癌患者分期中的诊断准确性存在差异。
研究设计与样本
- 前瞻性多中心先导研究,纳入2018年12月至2021年1月间临床II/III期或局部区域复发、1或2级、雌激素受体阳性的乳腺癌患者,共41例女性参与者(中位年龄56岁,IQR 48-71岁),44个乳腺肿瘤;所有参与者除常规影像和18F-FDG PET标准分期外,另接受18F-FES PET检查,两种PET独立评估,疾病分期分别基于常规影像联合18F-FDG PET或18F-FES PET独立确定,可疑恶性病灶经组织病理学验证后确定最终分期;临床试验注册号NCT03726931。
诊断标准与关键数值
- 18F-FDG PET正确分期29/41例(71%),18F-FES PET正确分期34/41例(83%)(P = .18);浸润性小叶癌中18F-FDG PET正确分期7/10例(70%),18F-FES PET正确分期9/10例(90%)(P = .38);1级肿瘤中18F-FDG PET正确分期7/12例(58%),18F-FES PET正确分期11/12例(92%)(P = .06);区域淋巴结分期中18F-FDG PET错误分期6/44例(14%),18F-FES PET全部正确(P = .02);两种方法检测转移性疾病的敏感度均为100%(95% CI:59,100),特异度均为91%(95% CI:76,98)。
临床应用与阅片要点
- 原文结论为在这项前瞻性先导研究中没有证据表明18F-FES PET与18F-FDG PET在1或2级雌激素受体阳性乳腺癌分期中的诊断准确性存在差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background According to current guidelines, staging of patients with locally advanced breast cancer and local-regional recurrent breast cancer is preferably performed with PET using 2-fluorine 18-fluoro-2-deoxy-d-glucose (18F-FDG). However, 18F-FDG PET might underperform in low-grade estrogen receptor (ER)-positive breast cancer. Alternatively, 16α-18F-fluoro-17β-estradiol (18F-FES) has emerged as a powerful tracer for in vivo visualization of ER-positive lesions. Purpose To assess whether 18F-FES PET improves staging of grade 1 or 2 ER-positive breast cancer compared with 18F-FDG PET. Materials and Methods Patients with clinical stage II/III or local-regional recurrent, grade 1 or 2, ER-positive breast cancer were included between December 2018 and January 2021 in this prospective multicenter pilot study. All participants underwent an 18F-FES PET examination in addition to standard staging with conventional imaging and 18F-FDG PET. Both PET scans were independently assessed. The disease stage was determined independently based on conventional imaging and 18F-FDG PET or 18F-FES PET. Relevant lesions suspected of malignancy were verified histopathologically, after which a final stage was determined. Results A total of 41 female participants (median age, 56 years [IQR, 48-71 years]) with 44 breast tumors were included. Overall, 29 of 41 participants (71%) were correctly staged at 18F-FDG PET compared with 34 of 41 (83%) at 18F-FES PET (P = .18). Seven of 10 and nine of 10 cases of lobular breast cancer were correctly staged at 18F-FDG and 18F-FES PET, respectively (70% vs 90%; P = .38) and seven of 12 and 11 of 12 cases of grade 1 tumors, respectively (58% vs 92%; P = .06). Regional lymph nodes were incorrectly staged at 18F-FDG PET in six of 44 cases (14%), whereas all cases were correctly staged at 18F-FES PET (P = .02). Both imaging methods had a sensitivity of 100% (95% CI: 59, 100) and a specificity of 91% (95% CI: 76, 98) for the detection of metastatic disease. Conclusion In this prospective pilot study, there was no evidence of a difference in diagnostic accuracy of 18F-FES PET and 18F-FDG PET in staging patients with grade 1 or 2 ER-positive breast cancer. Clinical trial registration no. NCT03726931 Published under a CC BY 4.0 license Supplemental material is available for this article. See also the editorial by Fowler in this issue.
引用
- Knip JJ, Iqbal R, Bonjer EC, et al. The Diagnostic Accuracy of 18F-FDG PET and 18F-FES PET for Staging Grade 1-2 Estrogen Receptor-Positive Breast Cancer. Radiology. 2025. PMID: 40035673. doi:10.1148/radiol.241850
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。